- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06534437
MEN1703 (SEL24) para tratar el linfoma no Hodgkin de células B agresivo en recaída o refractario (JASPIS-01) (JASPIS-01)
Un ensayo clínico abierto de fase 2 de MEN1703 como monoterapia y en combinación con glofitamab en pacientes con linfoma no Hodgkin agresivo de células B en recaída o refractario
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time:
- Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma
- Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maximum of 12 cycles. One cycle is 21 days. Group 2 with be treated until the disease progresses, therefore treatment duration is dependent on the number of treatment cycles a participant receives prior to progression.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study consists of 3 parts, to investigate MEN1703 (Dapolsertib hydrochloride) in combination with glofitamab in patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) or MEN1703 alone in patients who have exhausted all standard treatment options (group 2).
Part 1 (safety run-in) and Part 2 (enrichment): patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive either 150 mg or 125 mg of MEN1703 along with glofitamab. Patients who have exhausted all standard treatment options (group 2) will receive 125 mg of MEN1703 as a single-agent.
Part 3 (optional randomized comparison): Patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody therapy will be randomized to receive either MEN1703 (Dapolsertib hydrochloride) at a dose selected from part 2 in combination with glofitamab or glofitamab alone.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Head of Clinical Operations
- Número de teléfono: +48 123140200
- Correo electrónico: clinicaltrials@ryvu.com
Ubicaciones de estudio
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hospital Universitari Vall D Hebron
-
Investigador principal:
- Crisitna Garcia Herce, MD PhD
-
Madrid, España, 28033
- Reclutamiento
- MD Anderson Cancer Center
-
Investigador principal:
- Adolfo De La Fuente Burguera, MD PhD
-
Madrid, España
- Reclutamiento
- Hospital Universitario Puerta de Hierro Majadahonda
-
Investigador principal:
- Mariano Provencio Pulla, MD PhD
-
Madrid, España, 28027
- Reclutamiento
- Clinica Universidad De Navarra
-
Investigador principal:
- Miguel Angel Canales Albendea, MD PhD
-
Murcia, España, 30120
- Aún no reclutando
- Hospital Clínico Uni versitario Virgen de la Arrixaca
-
Investigador principal:
- Ignacio Espanol Morales, Dr
-
Pamplona, España, 31008
- Reclutamiento
- Clinica Universidad De Navarra
-
Investigador principal:
- Miguel Angel Canales Albendea, MD PhD
-
Pamplona, España, 31008
- Reclutamiento
- Hospital Universitario De Navarra
-
Investigador principal:
- Jose Maria Arguinano Perez, MD PhD
-
Salamanca, España, 37007
- Reclutamiento
- Hospital Universitario De Salamanca
-
Investigador principal:
- Norma Carmen Gutierrez, Prof.
-
Seville, España, 41009
- Reclutamiento
- Hospital Universitario Virgen De La Macarena
-
Investigador principal:
- Natalia Palazon, MD PhD
-
Zaragoza, España
- Reclutamiento
- Hospital Universitario Miguel Servet
-
Investigador principal:
- Araceli Rubio Martinez, MD PhD
-
-
-
-
-
Le Mans, Francia, 72037
- Reclutamiento
- Centre Hospitalier Le Mans
-
Investigador principal:
- Kamel Laribi, MD PhD
-
Lille, Francia
- Reclutamiento
- CHU de Lille - Hôpital Claude Huriez
-
Investigador principal:
- Franck Morschhauser, Prof.
-
Limoges, Francia, 87042
- Reclutamiento
- CHU de Limoges - CHU Dupuytren
-
Investigador principal:
- Julie Abraham, MD PhD
-
Lyon, Francia, 69310
- Reclutamiento
- Hospices Civils De Lyon - Hôpital Lyon Sud
-
Investigador principal:
- Herve Ghesquieres, Prof.
-
Montpellier, Francia, 34490
- Reclutamiento
- CHU Montpellier - Hôpital Saint Eloi
-
Investigador principal:
- Guillaume Cartron, MD PhD
-
Paris, Francia, 75651
- Reclutamiento
- APHP - Hôpital Pitié-Salpêtrière
-
Investigador principal:
- Sylvain Choquet, MD PhD
-
Pessac, Francia, 33600
- Reclutamiento
- CHU de Bordeaux - Hôpital Haut-Lévêque
-
Investigador principal:
- Francois Xavier Gros, MD PhD
-
-
-
-
-
Biała Podlaska, Polonia
- Terminado
- Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
-
Bydgoszcz, Polonia
- Reclutamiento
- IN-VIVO Bydgoszcz Sp. z o.o.
-
Investigador principal:
- Jarosław Czyż, Prof.
-
Gdansk, Polonia
- Aún no reclutando
- Klinika Hematologii I Transplantologii Uck
-
Investigador principal:
- Jan Zaucha, Prof.
-
Gdynia, Polonia
- Reclutamiento
- Szpitale Pomorskie Sp. z o.o.
-
Investigador principal:
- Adam Witkowski, MD PhD
-
Gliwice, Polonia
- Reclutamiento
- Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy
-
Contacto:
- Małgorzata Krawczyk-Kuliś, Prof.
-
Investigador principal:
- Małgorzata Krawczyk-Kuliś, Prof.
-
Katowice, Polonia
- Terminado
- Pratia Hematologia Sp. z o.o.
-
Krakow, Polonia
- Reclutamiento
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Investigador principal:
- Agnieszka Giza, MD PhD
-
Krakow, Polonia
- Reclutamiento
- Pratia MCM Kraków
-
Contacto:
- Wojciech Jurczak, Prof.
-
Investigador principal:
- Wojciech Jurczak, Prof.
-
Olsztyn, Polonia
- Reclutamiento
- Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
-
Contacto:
- Janusz Hałka, MD PhD
-
Investigador principal:
- Janusz Hałka, MD PhD
-
Skórzewo, Polonia
- Reclutamiento
- Aidport Sp. z o.o.
-
Investigador principal:
- Michał Kwiatek, Dr
-
Torun, Polonia
- Reclutamiento
- Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
-
Contacto:
- Dominik Chraniuk, MD
-
Investigador principal:
- Dominik Chraniuk, MD
-
Warsaw, Polonia
- Terminado
- Lux Med Onkologia Sp. z o.o.
-
Warsaw, Polonia
- Terminado
- Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy
-
-
-
-
-
Glasgow, Reino Unido
- Reclutamiento
- Beatson West of Scotland Cancer Centre
-
Investigador principal:
- Mark Rafferty, Dr
-
Manchester, Reino Unido
- Reclutamiento
- The Christie NHS Foundation Trust
-
Investigador principal:
- Kim Linton, Dr
-
Plymouth, Reino Unido
- Reclutamiento
- Plymouth Hospitals NHS Trust
-
Investigador principal:
- David Burns, Dr
-
Sutton, Reino Unido
- Reclutamiento
- The Royal Marsden Hospital
-
Investigador principal:
- David Cunningham, Dr
-
Tooting, Reino Unido
- Reclutamiento
- St George's Hospital
-
Investigador principal:
- Ruth Pettengell, Dr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥18 years old
- Documented histological confirmation of aggressive B-cell non-Hodgkin lymphoma including DLBCL NOS and transformed indolent B-cell lymphoma
- Relapsed or refractory disease having received at least 2 prior lines of systemic treatment and, naïve to anti-CD3xCD20 bispecific antibody treatment (group 1) or exhausted all standard, available treatment options (group 2)
- At least 1 measurable site of disease based on computed tomography (CT) or positron emission tomography (PET)-CT scan with involvement of 2 or more clearly demarcated lesions and or nodes.
- Availability of lymph node tissue at Screening (or archival sample) (part 2 participants only)
- Life expectancy of ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
- Adequate organ function at Screening
- Adequate hematologic function
Exclusion Criteria:
-
Primary central nervous system (CNS) lymphoma or CNS involvement by lymphoma at screening.
-
Received anti-cancer treatments, including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy, or investigational drugs within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug. Prior treatment with CAR-T cell or an anti-CD3xCD20 bispecific antibody therapy (permitted for Group 2 only), requires a wash out period of ≥4 weeks.
-
Concurrent participation in another therapeutic clinical study.
-
Ongoing clinically significant toxicity (for example, alopecia is not clinically significant) from any prior anti-cancer therapy that has not resolved to Grade 1 or less prior to the first dose of study drug.
-
Prior treatment with a PIM inhibitor.
-
Group 1 only: Any prior therapy with a bispecific antibody targeting CD3 and CD20.
-
Known risk of allergy to the study drugs, MEN1703 (group 1 and 2) or glofitamab (group 1) or their excipients
-
Contraindication to all uric acid lowering agents.
-
Major surgery within 1 month prior to first dose of study drug.
-
Hematopoietic stem cell transplant within 4 months prior to first dose of study drug.
-
Requires systemic immune-modulating therapy (regardless of dose) or has confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression.
-
Exposed to live or live attenuated vaccine(s) within 4 weeks prior to signing the informed consent form (ICF).
-
Evidence of ongoing and uncontrolled systemic bacterial, fungal, or viral infection, except for documented Grade Common Terminology Criteria for Adverse Events (CTCAE) ≤2 infections with evidence of improvement or without evidence of worsening infection.
-
Known human immunodeficiency virus (HIV) infection
-
Current active liver disease from any cause
-
Ongoing drug-induced pneumonitis.
-
Ongoing inflammatory bowel disease.
-
Active known second malignancy
-
Received an agent known to be a sensitive CYP2D6 substrate or a CYP2D6 substrate with a narrow therapeutic range, a strong or moderate CYP2D6 inhibitor, or a BCRP inhibitor within 14 days or 5 half-lives (whichever is shorter), prior to the first dose of study drug.
-
Cardiac dysfunction is defined as myocardial infarction within 6 months of study entry, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, or poorly controlled angina.
-
Receiving treatment for active, ongoing thromboembolic event. Note: Does not apply to prophylactic treatment to prevent or avoid reoccurrence of a prior resolved event. To review with Medical Monitor where further risk assessment is needed.
-
History of serious ventricular arrhythmia (e.g., VT or VF, ≥3 beats in a row), or QT interval corrected for heart rate (QTc) ≥480 ms.
Note: QTc values up to 500 ms will be acceptable where patient's medical history e.g., bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled.
-
Any disease, syndrome or condition which may significantly affect drug intake via oral route.
-
Planning to become pregnant or breastfeed during treatment and for 1 month after the last dose of study drug.
-
Any other prior or current medical condition, intercurrent illness, surgical history, physical or 12-lead electrocardiogram (ECG) findings, laboratory abnormalities, or extenuating circumstance (e.g., alcohol or drug addiction) that, in the investigator's opinion, could jeopardize patient safety or interfere with the objectives of the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: MEN1703 + glofitamab
• Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will be given MEN1703 orally at a dose of 150 mg daily for 7 days or 125 mg daily for 14 days, in 21-day cycles for a maximum of 12 cycles, in combination with glofitamab administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (parts 1, 2, 3)). All participants will be administered 1,000 mg of obinutuzumab as an IV infusion on cycle 1 day 1. • Participants who have exhausted all standard treatment options (group 2) will receive MEN1703 as a single-agent, at a dose of 125 mg orally every-day for 14 consecutive days in consecutive 21-day treatment cycles, until progressive disease (parts 1 and 2). |
MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
Otros nombres:
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells. |
|
Comparador activo: Gofitamab
Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive glofitamab as a single-agent administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (part 3). |
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1: Incidence and severity of adverse events (AE)
Periodo de tiempo: 12 months
|
Assessed as the number and grade of adverse events assessed by CTCAE v5.0 |
12 months
|
|
Part 2 and Part 3: Complete response (CR) (group 1)
Periodo de tiempo: 12 months
|
Assessed per Lugano Response Criteria for Malignant Lymphoma |
12 months
|
|
Part 2 and Part 3: Overall response rate (group 2)
Periodo de tiempo: 12 months
|
Assessed as the number of patients who achieve a complete response (CR) or partial response (PR), per Lugano Response Criteria, divided by the total number of evaluable patients |
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 2 and Part 3, Incidence and severity of AE
Periodo de tiempo: 12 months
|
Assessed as the number and grade of adverse events assessed by CTCAE v5.0 |
12 months
|
|
Maximum Plasma Concentration (Cmax)
Periodo de tiempo: 12 months
|
Assessment of the peak plasma concentration (Cmax) |
12 months
|
|
Maximum Plasma Concentration (Tmax)
Periodo de tiempo: 12 months
|
Assessment of the time to peak plasma concentration (Tmax) |
12 months
|
|
Area Under the Concentration Time-Curve (AUC)
Periodo de tiempo: 12 months
|
Assessed of the area under the plasma concentration versus time curve (AUC) |
12 months
|
|
Impact of treatment on patient reported outcomes (PRO)
Periodo de tiempo: 12 months
|
Assessed as changes in lymphoma symptoms, well-being, and general health status measured according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) consisting of 30 questions that assess five domains of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), global health status/quality of life (GHS/QoL), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All are scored from 0 to 100, with higher scores on the five domains and GHS/QoL being reflective of better health related (HR) QoL, and higher scores on the symptom scales and single items reflective of poor HRQoL. |
12 months
|
|
Impact of treatment on quality of life (QOL)
Periodo de tiempo: 12 months
|
Assessed as changes in lymphoma symptoms and health related quality of life (HRQoL) as measured using the 15-item Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) including physical, social/family, emotional, and functional well-being and includes a lymphoma-specific subscale. The scale range is 0 to 60, with a higher score reflecting a better HRQoL. |
12 months
|
|
Overall survival (OS)
Periodo de tiempo: 12 months
|
Assessed as the time from first treatment to death. |
12 months
|
|
Progression-free survival (PFS)
Periodo de tiempo: 12 months
|
Assessed as time from the time from first treatment to the first occurrence of disease progression or death. |
12 months
|
|
Duration of Response (DoR)
Periodo de tiempo: 12 months
|
Assessed as the time from first response (CR or PR) to the first occurrence of disease progression or death. |
12 months
|
|
Duration of Complete Response (DoCR)
Periodo de tiempo: 12 months
|
Assessed as the time from first complete response (CR) to the first occurrence of disease progression or death. |
12 months
|
|
Time to response
Periodo de tiempo: 12 months
|
Assessed as the time from the first treatment to the time of first response (CR or PR). |
12 months
|
|
Time to next treatment
Periodo de tiempo: 12 months
|
Assessed as the time from the first treatment to the start date of the first therapy received after the participant has ended study treatment and received subsequent anti-lymphoma therapy. |
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Comportamiento motor aberrante en la demencia
- Procesos Patológicos
- Neoplasias
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Síntomas de comportamiento
- Neoplasias por tipo histológico
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma
- Condiciones Patológicas, Signos y Síntomas
- Comportamiento
- Enfermedades hemic y linfáticas
- Comportamiento social
- Reaparición
- Linfoma No Hodgkin
- Agresión
- glofitamab
Otros números de identificación del estudio
- JASPIS-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .